3/3
05:54 pm
mlys
Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight [Yahoo! Finance]
Low
Report
Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight [Yahoo! Finance]
3/3
05:31 pm
mlys
Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight
Low
Report
Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight
3/3
05:31 pm
mlys
Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight
Low
Report
Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight
2/26
04:22 pm
mlys
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
2/26
04:05 pm
mlys
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2/16
06:27 pm
mlys
Is Mineralys Therapeutics (MLYS) Pricing Reflect The Recent Share Price Pullback [Yahoo! Finance]
Low
Report
Is Mineralys Therapeutics (MLYS) Pricing Reflect The Recent Share Price Pullback [Yahoo! Finance]
2/11
07:00 pm
mlys
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
1/30
12:53 am
mlys
Mineralys Therapeutics (MLYS) Files Lorundrostat NDA Following Positive Clinical Milestones [Yahoo! Finance]
Medium
Report
Mineralys Therapeutics (MLYS) Files Lorundrostat NDA Following Positive Clinical Milestones [Yahoo! Finance]
1/6
08:00 am
mlys
Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026
Low
Report
Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026
12/25
07:00 pm
mlys
Is It Too Late To Consider Mineralys Therapeutics After Its Huge 2025 Share Price Surge [Yahoo! Finance]
Low
Report
Is It Too Late To Consider Mineralys Therapeutics After Its Huge 2025 Share Price Surge [Yahoo! Finance]
12/24
07:01 pm
mlys
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow [Yahoo! Finance]
Low
Report
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow [Yahoo! Finance]
12/23
12:39 pm
mlys
Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears [Yahoo! Finance]
Low
Report
Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears [Yahoo! Finance]
12/19
10:04 am
mlys
Mineralys Therapeutics (NASDAQ:MLYS) was given a new $52.00 price target on by analysts at Stifel Nicolaus. They now have a "buy" rating on the stock.
Medium
Report
Mineralys Therapeutics (NASDAQ:MLYS) was given a new $52.00 price target on by analysts at Stifel Nicolaus. They now have a "buy" rating on the stock.
12/12
11:00 am
mlys
Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup
Low
Report
Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup